
    
      rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin,
      dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab
      maintenance therapy consisting of four weekly doses every six months for two years
    
  